Numerous outbreaks of MDR-TB have been reported, and the global burden remains high, in part because of diagnostic and treatment limitations; in 2020, about 71% of bacteriologically proven cases had access to testing for rifampin resistance (a surrogate for identifying MDR-TB), an improvement from the 61% reported in 2019.